Ascendis Pharma A/S - ADR (ASND) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2015 to Q4 2025

Type / Class
Equity / ADR
Symbol
ASND on Nasdaq
Shares outstanding
55,574,229
Price per share
$213.24
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
63,798,122
Total reported value
$12,683,766,165
% of total 13F portfolios
0.02%
Share change
+1,080,402
Value change
+$232,138,587
Number of holders
276
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Ascendis Pharma A/S - ADR (ASND) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WESTFIELD CAPITAL MANAGEMENT CO LP 9.2% $887,005,948 5,528,239 Westfield Capital Management Company, L.P. 31 Dec 2024
FMR LLC 8% $745,602,004 4,646,943 FMR LLC 31 Mar 2025
JANUS HENDERSON GROUP PLC 7.8% -2.5% $859,467,360 -$20,821,968 4,323,059 -2.4% JANUS HENDERSON GROUP PLC 30 Sep 2025
Capital International Investors 5.6% $548,747,120 3,109,225 Capital International Investors 30 Jun 2025
T. Rowe Price Investment Management, Inc. 4.8% -27% $530,338,200 -$182,106,580 2,667,563 -26% T. Rowe Price Investment Management, Inc. 30 Sep 2025

As of 30 Sep 2025, 276 institutional investors reported holding 63,798,122 shares of Ascendis Pharma A/S - ADR (ASND). This represents 115% of the company’s total 55,574,229 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Ascendis Pharma A/S - ADR (ASND) together control 97% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 19% 10,281,496 0% 25% $2,044,064,220
WESTFIELD CAPITAL MANAGEMENT CO LP 9.5% 5,259,909 -3.5% 4.4% $1,045,722,561
Avoro Capital Advisors LLC 9.2% 5,110,000 +2.6% 13% $1,015,919,100
FMR LLC 8% 4,471,733 -1.3% 0.05% $889,025,151
JANUS HENDERSON GROUP PLC 7.8% 4,323,059 -2.4% 0.39% $859,415,657
Artisan Partners Limited Partnership 6.7% 3,720,880 -6.8% 1.1% $739,748,153
Capital International Investors 5.5% 3,060,616 +0.45% 0.1% $608,481,067
T. Rowe Price Investment Management, Inc. 4.8% 2,666,618 -26% 0.32% $530,151,000
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 3.4% 1,882,781 -1% 0.12% $374,315,689
WELLINGTON MANAGEMENT GROUP LLP 3.2% 1,798,931 +96% 0.06% $357,645,472
PRICE T ROWE ASSOCIATES INC /MD/ 3.1% 1,726,228 -8% 0.04% $343,192,000
FRANKLIN RESOURCES INC 2.9% 1,589,956 -9.3% 0.08% $316,099,066
PERCEPTIVE ADVISORS LLC 2% 1,088,501 +13% 6.3% $216,404,884
Invesco Ltd. 1.7% 917,903 -3.1% 0.03% $182,488,296
Polar Capital Holdings Plc 1.5% 857,911 +2.4% 0.82% $170,561,286
PRINCIPAL FINANCIAL GROUP INC 1.4% 793,677 +2723% 0.08% $157,790,924
GOLDMAN SACHS GROUP INC 1.2% 653,012 +21% 0.02% $129,825,315
Vestal Point Capital, LP 1.1% 600,000 +200% 5.4% $119,286,000
AMERIPRISE FINANCIAL INC 1% 562,936 -4.3% 0.03% $111,917,306
AMERICAN CENTURY COMPANIES INC 0.98% 544,606 +2.6% 0.06% $108,274,297
FIL Ltd 0.83% 459,340 -1% 0.07% $91,321,385
BlackRock, Inc. 0.81% 451,497 -4.3% 0% $89,762,118
MORGAN STANLEY 0.73% 406,761 +60% 0% $80,868,155
Spyglass Capital Management LLC 0.7% 388,647 4.1% $77,266,910
ALLIANCEBERNSTEIN L.P. 0.68% 375,899 -0.48% 0.02% $74,732,480

Institutional Holders of Ascendis Pharma A/S - ADR (ASND) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 69,572 $14,835,473 +$873,573 $213.24 7
2025 Q3 63,798,122 $12,683,766,165 +$232,138,587 $198.81 276
2025 Q2 62,895,390 $10,855,906,781 -$373,773,069 $172.60 245
2025 Q1 65,180,066 $10,147,446,038 +$223,136,493 $155.86 241
2024 Q4 63,751,521 $8,776,308,689 +$115,863,512 $137.67 212
2024 Q3 62,595,716 $9,312,956,409 +$237,478,312 $149.31 218
2024 Q2 60,687,245 $8,276,478,215 -$25,623,552 $136.38 202
2024 Q1 60,791,422 $9,189,438,728 +$198,420,492 $151.17 188
2023 Q4 60,262,338 $7,590,188,894 -$95,295,592 $125.95 183
2023 Q3 60,279,508 $5,644,577,484 -$61,738,785 $93.64 157
2023 Q2 61,039,136 $5,447,708,812 -$42,606,636 $89.25 156
2023 Q1 60,982,797 $6,535,152,679 -$603,913,240 $107.22 160
2022 Q4 65,956,055 $8,054,269,679 -$66,421,048 $122.13 183
2022 Q3 66,716,414 $6,891,080,476 +$149,538,106 $103.26 177
2022 Q2 63,211,628 $5,875,622,934 +$99,259,708 $92.96 162
2022 Q1 61,928,932 $7,267,064,424 +$416,027,513 $117.36 169
2021 Q4 58,376,386 $7,851,336,290 -$60,447,865 $134.53 168
2021 Q3 58,008,737 $9,244,880,979 +$506,030,857 $159.39 162
2021 Q2 55,049,436 $7,239,726,130 +$277,622,452 $131.55 167
2021 Q1 52,687,197 $6,790,538,552 -$259,999,867 $128.88 172
2020 Q4 54,357,110 $9,065,494,890 +$123,538,090 $166.78 173
2020 Q3 53,548,292 $8,263,618,101 +$776,855,285 $154.32 150
2020 Q2 48,248,343 $7,132,005,530 +$39,025,561 $147.90 149
2020 Q1 47,871,754 $5,391,239,456 +$191,350,357 $112.61 143
2019 Q4 46,149,738 $6,420,287,137 -$13,680,500 $139.12 139
2019 Q3 46,122,563 $4,442,511,426 -$194,325,083 $96.32 127
2019 Q2 47,663,417 $5,487,484,115 +$237,283,765 $115.15 132
2019 Q1 45,989,019 $5,412,737,939 +$716,635,309 $117.70 137
2018 Q4 40,100,469 $2,509,199,237 -$10,826,186 $62.65 102
2018 Q3 40,188,306 $2,847,498,166 +$44,455,437 $70.86 94
2018 Q2 39,572,750 $2,632,379,192 +$96,237,781 $66.52 100
2018 Q1 38,126,373 $2,493,396,132 +$345,130,853 $65.40 89
2017 Q4 30,513,340 $1,222,363,447 +$50,139,269 $40.06 64
2017 Q3 28,774,674 $1,042,816,000 +$204,057,698 $36.25 59
2017 Q2 23,269,447 $646,000,000 +$80,276,736 $27.76 34
2017 Q1 20,898,775 $585,169,000 +$9,050,400 $28.00 34
2016 Q4 20,561,240 $416,160,000 +$130,784,664 $20.24 31
2016 Q3 13,995,656 $281,311,000 +$4,791,129 $20.10 22
2016 Q2 13,876,594 $184,147,000 +$10,182,326 $13.27 23
2016 Q1 12,036,579 $223,242,000 +$9,842,726 $18.55 25
2015 Q4 10,090,990 $184,865,000 +$7,675,460 $18.32 24
2015 Q3 8,925,979 $157,986,000 -$15,929 $17.70 24
2015 Q2 8,953,630 $157,820,000 +$7,731,541 $17.68 32
2015 Q1 8,477,992 $145,818,000 +$145,818,000 $17.35 35